文献速递妇科

从美国支付方角度看多塔利单抗联合卡铂-紫杉醇一线治疗晚期或复发性子宫内膜癌的成本效果

Cost-effectiveness of dostarlimab plus carboplatin-paclitaxel for primary advanced or recurrent endometrial cancer from a US payer perspective.
PubMed 文献 · Gynecol Oncol · 2024-11-08

本研究采用美国支付方视角的分区生存模型,基于RUBY试验数据评估多塔利单抗联合卡铂-紫杉醇一线治疗原发性晚期或复发性子宫内膜癌的成本效果。在错配修复缺陷/微卫星高度不稳定(dMMR/MSI-H)人群中,增量成本效果比为每质量调整生命年57,151美元;在总人群中为143,783美元。在15万美元支付意愿阈值下,两群体具有成本效果的概率分别为100%和53.7%。

要点

  • dMMR/MSI-H人群:多塔利单抗联合方案较单纯化疗增加6.9个生命年和5.4个质量调整生命年,增量成本效果比57,151美元/质量调整生命年。
  • 总人群:多塔利单抗联合方案较单纯化疗增加2.0个生命年和1.5个质量调整生命年,增量成本效果比143,783美元/质量调整生命年。
  • 在15万美元支付意愿阈值下,dMMR/MSI-H和总人群具有成本效果的概率分别为100%和53.7%。

核心结论

  • 多塔利单抗联合卡铂-紫杉醇对于美国dMMR/MSI-H和总人群的原发性晚期或复发性子宫内膜癌患者具有成本效果。

研究设计与样本

  • 研究采用分区生存模型,包含无进展疾病、进展疾病和死亡三个互斥健康状态,基于美国基础案例和第三方支付方视角。
  • 临床数据来源于RUBY试验和已发表文献,成本数据来源于美国数据库。
  • 主要结局为生命年、质量调整生命年、增量成本和增量成本效果比,并进行了单因素和概率敏感性分析。

主要发现

  • 在dMMR/MSI-H人群中,多塔利单抗联合卡铂-紫杉醇相比单纯卡铂-紫杉醇增加6.9个生命年和5.4个质量调整生命年,增量成本高307,696美元,增量成本效果比为每质量调整生命年57,151美元。
  • 在总人群中,多塔利单抗联合卡铂-紫杉醇相比单纯卡铂-紫杉醇增加2.0个生命年和1.5个质量调整生命年,增量成本高215,876美元,增量成本效果比为每质量调整生命年143,783美元。
  • 增量成本效果比对总生存风险比最为敏感。
  • 在150,000美元支付意愿阈值下,多塔利单抗联合卡铂-紫杉醇在dMMR/MSI-H人群和总人群中具有成本效果的概率分别为100%和53.7%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Dostarlimab in combination with carboplatin-paclitaxel (CP) improves progression-free survival in patients with primary advanced or recurrent endometrial cancer (pA/rEC), including in patients whose cancer is mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H). This study examined the cost-effectiveness of dostarlimab plus CP as a first-line treatment in the dMMR/MSI-H and overall populations. METHODS: A partitioned survival model with three mutually exclusive health states (progression-free disease, progressed disease, death) was developed using a US base case and a third-party payer perspective. Clinical data were from the RUBY trial and published sources. Costs were from US databases. The primary outcomes were life-years (LYs), quality-adjusted life-years (QALYs), incremental costs, and incremental cost-effectiveness ratios (ICERs). One-way and probabilistic sensitivity analyses were also performed. RESULTS: In the dMMR/MSI-H population, the model predicted gains of 6.9 LYs and 5.4 QALYs with dostarlimab plus CP compared with CP; costs were $307,696 higher with dostarlimab plus CP, resulting in an ICER of $57,151 per QALY gained. In the overall population, gains of 2.0 LYs and 1.5 QALYs were predicted with dostarlimab plus CP compared with CP; costs were $215,876 higher, resulting in an ICER of $143,783 per QALY gained. ICERs were most sensitive to the overall survival hazard ratio. At a willingness-to-pay threshold of $150,000, dostarlimab plus CP had cost-effectiveness probabilities of 100 % and 53.7 % in the dMMR/MSI-H and overall populations, respectively. CONCLUSIONS: Dostarlimab plus CP is cost-effective as a treatment for the dMMR/MSI-H and overall populations of US patients with pA/rEC.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Coleman RL, Lubinga SJ, Shen Q, et al. Cost-effectiveness of dostarlimab plus carboplatin-paclitaxel for primary advanced or recurrent endometrial cancer from a US payer perspective. Gynecol Oncol. 2024. PMID: 39520771. doi:10.1016/j.ygyno.2024.10.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。